Genotype-Guided Cardiac Device Intervention in <i>LMNA</i> -Related Cardiac Conduction Disorder: The Need for Timely Genetic Testing

Sudden cardiac death is a catastrophic event, making its prevention important. However, patient selection for primary prevention remains controversial. We report two cases of cardiac conduction disorder initially treated with permanent pacemaker implantation. Genetic testing later revealed novel pathogenic variants in LMNA, leading to an upgrade to implantable cardioverter-defibrillator for primary prevention of sudden cardiac death. These cases highlight the importance of early genetic analysis to guide optimal device therapy. The delay in obtaining genetic results necessitated reoperation, underscoring the need for preceding genomic sequencing and physician awareness to improve clinical decision-making and patient outcomes.

Authors

Institutions

Publication Details

Journal
European Journal of Heart Failure
Published
2025-05-24
DOI
https://doi.org/10.1002/ejhf.3695
Primary Topic
Cardiac pacing and defibrillation studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genotype-Guided Cardiac Device Intervention in LMNA -Related Cardiac Conduction Disorder: The Need for Timely Genetic Testing

Norihiko Takeda, Eisuke Amiya, Norifumi Takeda, Junichi Ishida et al.
2 links
European Journal of Heart Failure
Cardiac pacing and defibrillation studies
article

Genotype-Guided Cardiac Device Intervention in LMNA -Related Cardiac Conduction Disorder: The Need for Timely Genetic Testing

Norihiko Takeda, Eisuke Amiya, Norifumi Takeda, Junichi Ishida, Masamichi Ito, Tsukasa Oshima, Yu Shimizu, Seitaro Nomura, Katsuhito Fujiu, Masaru Hatano, Hiroyuki Morita, Issei Komuro, Zhehao Dai, Takashi Hiruma, Manami Katoh, Kenichiro Yamagata, Kanna Fujita, Toshiyuki Ko, Ryo Abe, Shunsuke Inoue
article en

Abstract

Sudden cardiac death is a catastrophic event, making its prevention important. However, patient selection for primary prevention remains controversial. We report two cases of cardiac conduction disorder initially treated with permanent pacemaker implantation. Genetic testing later revealed novel pathogenic variants in LMNA, leading to an upgrade to implantable cardioverter-defibrillator for primary prevention of sudden cardiac death. These cases highlight the importance of early genetic analysis to guide optimal device therapy. The delay in obtaining genetic results necessitated reoperation, underscoring the need for preceding genomic sequencing and physician awareness to improve clinical decision-making and patient outcomes.

European Journal of Heart FailureVol. 27(9)
The University of Tokyo (JP), International University of Health and Welfare (JP)
Cell Science Research Foundation, Novartis Foundation, Japan Foundation for Applied Enzymology, Uehara Memorial Foundation, Daiichi-Sankyo, University of Tokyo, Astellas Pharma, Japanese Circulation Society, Astellas Foundation for Research on Metabolic Disorders, SENSHIN Medical Research Foundation, Kanae Foundation for the Promotion of Medical Science, NOVARTIS Foundation (Japan) for the Promotion of Science, Japan Heart Foundation
Peace, Justice and strong institutions
Openalex Percentile: Top 79%
Cardiac pacing and defibrillation studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.